The research, led by Edoardo Bianchini of Sapienza University of Rome and the University Grenoble Alpes, together with colleagues in Italy, France, and Germany, tackled a methodological problem that has hampered earlier work in this field. People with Parkinson’s disease vary enormously in age, disease duration, symptom severity, and medication profiles, so any observed difference between those with and without nocturnal hypokinesia could simply reflect underlying differences in how advanced their disease is rather than any specific effect of the nighttime symptom itself. To address this, the team used propensity score matching, a statistical technique borrowed from epidemiology that pairs individuals so that the groups are balanced across key clinical and demographic variables. From their cohort, they assembled eighty-eight participants with mild-to-moderate Parkinson’s disease, divided evenly into forty-four people with nocturnal hypokinesia and forty-four without, matched to be as comparable as possible on the characteristics that would otherwise confound the comparison.

Once the groups were constructed, the researchers subjected participants to a battery of supervised mobility tests performed under controlled laboratory conditions. These included a twenty-metre forward walking test, an instrumented version of the Timed-Up-and-Go test in which sensors capture the fine details of how a person rises from a chair, walks, turns, and sits back down, and a three-metre backward walking test, a demanding challenge for balance and motor control that is particularly sensitive to Parkinsonian motor dysfunction. The instrumented Timed-Up-and-Go is especially informative because turning is one of the movements most affected by the disease, and the embedded sensors allowed the team to quantify turning velocity with a precision that stopwatch-based clinical ratings cannot achieve. Backward walking, meanwhile, requires the brain to generate a motor pattern that is rarely rehearsed in daily life, making it a sensitive probe of the basal ganglia circuits that Parkinson’s disease progressively damages.

The results painted a consistent picture. Compared with their matched counterparts, people with nocturnal hypokinesia performed worse across most of the supervised mobility measures. They walked more slowly in the forward and backward directions, turned with reduced velocity during the instrumented Timed-Up-and-Go, and showed poorer overall functional mobility. The backward walking test proved particularly discriminating, with the nocturnal hypokinesia group moving noticeably slower when asked to walk in reverse. These differences emerged even though the two groups had been carefully balanced on the clinical variables that usually drive mobility performance, which strengthens the argument that the nighttime symptom itself is linked to a broader disturbance of movement regulation that persists into waking hours.

Crucially, the study did not stop at the laboratory door. Each participant wore a commercial activity tracker, the Garmin Vivosmart 4, for five consecutive days, allowing the researchers to capture average daily steps as a measure of unsupervised, real-world mobility. This distinction between supervised and unsupervised measurement matters enormously in movement disorders research. Clinic tests capture what a person can do when prompted and observed by an examiner, while free-living monitoring captures what a person actually does when no one is watching, a quantity shaped not only by motor capacity but also by motivation, habit, environment, and psychological state. The activity-tracker data revealed that the nocturnal hypokinesia group accumulated fewer average daily steps than the matched control group, indicating that the mobility deficit extended beyond the clinic and into the texture of everyday life.

The researchers then examined how the severity of nocturnal hypokinesia related to these outcomes. Across the cohort, worse nighttime hypokinesia correlated negatively with most of the supervised mobility measures and with daily step counts, meaning that the more severely a person’s movements were restricted at night, the worse their daytime performance tended to be. This dose-response pattern is an important feature of the findings, because a simple presence-or-absence difference could arise from chance or from an unmeasured confounder, whereas a graded relationship between symptom severity and mobility impairment is more suggestive of a genuine underlying link between nocturnal and diurnal motor function.

Yet the authors were careful to flag the preliminary nature of part of their evidence. In sensitivity analyses, they repeated the group comparisons while statistically controlling for fear of falling, a psychological factor that is common in Parkinson’s disease and known to constrain movement. When fear of falling was accounted for, the differences between the groups in supervised mobility shrank to statistical non-significance. This does not erase the observed pattern, but it raises the possibility that at least some of the clinic-based differences could be mediated by anxiety about falling rather than by a direct motor consequence of nocturnal hypokinesia. Fear of falling is itself a clinically meaningful target, and its role as a potential bridge between nighttime movement difficulties and daytime hesitancy is a question the study opens rather than closes.

Notably, the association between nocturnal hypokinesia severity and daily step count showed greater robustness in these sensitivity analyses than the supervised measures did. In other words, the link between how badly someone moves at night and how much they actually move during the day withstood the statistical adjustment for fear of falling better than the laboratory-based differences did. This asymmetry is intriguing. It suggests that free-living physical activity, measured continuously by a wrist-worn device, may capture a dimension of the nocturnal-daytime relationship that brief clinic tests miss, and it underscores the growing value of consumer wearable technology as a research instrument in neurology. A five-day monitoring window with an off-the-shelf tracker is far cheaper and more scalable than instrumented gait laboratories, and the findings hint that such devices could play a role in identifying patients whose nighttime symptoms are quietly eroding their daily activity.

The mechanistic story behind these associations remains to be worked out. Nocturnal hypokinesia is thought to reflect the interplay of declining dopaminergic medication coverage overnight, disrupted sleep architecture, and rigidity that worsens during periods of immobility. If the same circuits that fail to liberate movement at night are also operating at reduced efficiency during the day, the symptom could serve as a window onto a broader circadian dimension of Parkinsonian motor control that current clinical assessments, almost all conducted in daytime clinic hours, systematically overlook. Alternatively, poor nights could produce tired and stiff mornings, reducing daytime activity through fatigue and discomfort. The present study, being cross-sectional, cannot distinguish between these possibilities, and the authors themselves emphasize that their findings suggest an association rather than prove causation.

Even with those caveats, the practical implications are clear. Nocturnal hypokinesia is frequently underrecognized in routine care, partly because patients may not spontaneously report difficulties that occur while they are alone in bed, and partly because clinical rating scales focus overwhelmingly on daytime function. The study argues that nighttime movement should be actively screened for, and that when it is found, interventions should target both the nocturnal and the diurnal sides of the problem. Adjusting evening medication timing, optimizing nighttime sleep conditions, and designing physical-activity programs that account for fear of falling are all plausible avenues. For a disease in which mobility loss is the single most feared trajectory, the message from this research is that the night is not a pause in Parkinson’s disease but a continuation of it, and that protecting a patient’s ability to move may require paying attention to the hours when no one, until now, has been measuring.

Subject of Research: The association between nocturnal hypokinesia and supervised and unsupervised daytime mobility in mild-to-moderate Parkinson's disease

Article Title: The impact of nocturnal hypokinesia on supervised and unsupervised mobility in people with Parkinson’s disease

Article References: Bianchini, E., Lombardo, P., Milane, T., Rinaldi, D., De Carolis, L., Alborghetti, M., Suppa, A., Salvetti, M., Hansen, C., & Vuillerme, N. (2026). The impact of nocturnal hypokinesia on supervised and unsupervised mobility in people with Parkinson’s disease. npj Parkinson's Disease. https://doi.org/10.1038/s41531-026-01587-2

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01587-2

Keywords: Parkinson's disease, nocturnal hypokinesia, mobility, gait analysis, wearable activity tracker, Timed-Up-and-Go, backward walking, fear of falling, daily steps, propensity score matching, sleep, digital biomarkers

The research, led by Berkan Koyak and N. Ahmad Aziz at University Hospital Bonn and the German Center for Neurodegenerative Diseases, together with computer scientists at TU Dortmund University, harnessed a technology more familiar from animated avatars than from neurology clinics. Their application, ExpressionTracker, is built on Apple’s ARKit framework and adapted from software originally developed for photorealistic three-dimensional avatar creation. Using the TrueDepth sensor of an iPad Pro, the system fits a personalised three-dimensional facial mesh to each participant and quantifies 52 predefined blendshape coefficients, each corresponding to a named facial movement such as lowering the lower lip or widening the eyes. The coefficients are normalised from zero to one relative to each individual’s own neutral expression, providing person-specific calibration of baseline facial anatomy.

The protocol was strikingly simple. Seventy participants, 34 people with Parkinson’s disease and 36 healthy controls, sat 30 centimetres from the tablet’s front camera in a room lit only by fluorescent ceiling lights. After establishing a neutral baseline, they performed 52 voluntary facial movements guided by animated demonstrations, with a four-second relaxation pause after each task. The entire assessment took five to ten minutes. From the 53 recorded poses, the researchers derived three measurement conditions: neutral resting weights, peak voluntary activation, and the delta between the two, which captures movement amplitude. On top of these 156 base features, they engineered aggregation statistics, multiplicative interaction terms pairing facial effectors across different tasks, and 60 left-minus-right asymmetry indices, producing a feature space of 261 dimensions.

The results went well beyond the expected finding that people with Parkinson’s move their faces less. Six features survived stringent multiple-testing correction with moderate-to-large effect sizes, and the most informative were not simple amplitude measures. The dynamic range of right lower lip depression was markedly reduced in patients, differing between groups in both the delta and activated conditions with a rank-biserial correlation of up to 0.722. Both outer brows rested significantly higher in patients, a bilaterally elevated resting brow position that had not previously been systematically described in Parkinson’s disease. An asymmetry index for the left mouth frown was significantly greater in patients, and an interaction feature combining right eye widening with right lower lip depression showed one of the largest between-group effects of all, hinting at a right-sided hemihypomimia in this cohort.

That interaction result is scientifically important because facial expression is inherently synergistic, requiring coordinated combinations of activated and relaxed muscle groups. Prior automated approaches have almost exclusively measured how far individual landmarks move, ignoring both lateralised impairment and cross-effector coupling. Here, the interaction between mouth-left and mouth-smile-right features explained 42 percent of the variance in clinician-rated hypomimia, the strongest association in the entire correlation analysis, while mouth-smile-right alone explained 38 percent. Reduced voluntary eyebrow depression correlated with more advanced Hoehn and Yahr stage, and reduced capacity for lip pursing correlated with higher levodopa equivalent dose. These patterns suggest that blendshape analysis captures distinct, anatomically plausible dimensions of motor dysfunction that a single global expressivity rating cannot resolve.

The lower face’s prominence in the findings is anatomically coherent. The upper face benefits from bilateral cortical motor innervation and appears comparatively resilient to unilateral nigrostriatal degeneration, whereas the lower face relies predominantly on contralateral corticobulbar input and is more vulnerable to Parkinson’s pathology. The predominance of perioral features also aligns with earlier automated video studies showing that reduced lower lip movement is among the strongest correlates of dopaminergic loss and limb bradykinesia. The elevated resting brow, by contrast, echoes a well-established compensatory frontalis hyperactivity seen in progressive supranuclear palsy, and the authors caution that its presence in Parkinson’s disease requires validation before any neuroanatomical interpretation.

To test diagnostic value, the team ran eight machine-learning classifiers through a rigorously nested cross-validation pipeline in which every data-dependent step, including age and sex residualisation, imputation, scaling, elastic-net feature selection, and hyperparameter tuning, was fitted only on training folds. The gradient boosting machine performed best, achieving an area under the receiver operating characteristic curve of 0.834, followed by XGBoost at 0.810 and LightGBM at 0.804. At a fixed decision threshold, the best model reached an accuracy of 0.786, sensitivity of 0.735, and specificity of 0.833. Crucially, the engineered ARKit features outperformed an amplitude-only baseline, which peaked at an AUC of 0.752, and a demographic confounder-only baseline using age and sex, which peaked at 0.681, demonstrating that the diagnostic signal is not an artefact of cohort demographics. A label-permutation test with 1000 shuffles confirmed that discrimination exceeded chance for seven of the eight classifiers.

Interpretability analysis using SHAP values reinforced the central message. The most influential feature in the best model was the dynamic range of right lower lip depression, followed by baseline lateral gaze position, the asymmetry of inward gaze change, right eye widening, and left downward gaze. Notably, engineered OpenFace action-unit features computed on the same frames failed to discriminate patients from controls, a contrast the authors interpret cautiously since frame selection was performed by ARKit. The comparison nevertheless underscores a key methodological advantage: ARKit blendshape coefficients are both person-referenced and anatomically interpretable, and the TrueDepth sensor’s active depth encoding is by design less dependent on ambient lighting and skin texture than pixel-based or convolutional approaches known to be sensitive to those factors.

The authors are candid about limitations. The between-group and correlation analyses retain dependence on clinician-rated scores, all clinical assessments came from a single unblinded rater, and apathy and depression, which can mimic hypomimia, were not systematically assessed. The method requires frontal head pose, the sample was modest and single-site without external validation or test-retest data, and all participants had established diagnoses, leaving performance in prodromal populations unknown. The protocol captured only cued voluntary movements, not the spontaneous expressions also affected in Parkinson’s disease. And ARKit itself is proprietary and closed-source, designed for consumer animation rather than clinical measurement, with blendshape coefficients that saturate at their upper bound in the most severely affected individuals.

Even with these caveats, the study makes a compelling case that parkinsonian hypomimia is a multidimensional phenomenon encompassing diminished amplitude, bilaterally elevated resting brow tone, perioral cross-task interaction, and hemifacial asymmetry, all extractable in under ten minutes from a consumer tablet. With external validation in larger and more diverse cohorts, ExpressionTracker could become a candidate digital biomarker for community screening, longitudinal disease monitoring, and drug-efficacy assessment in clinical trials, precisely the objective, standardised measurement infrastructure that disease-modifying therapy development has been waiting for.

Subject of Research: Objective quantification of Parkinsonian hypomimia using facial blendshape analysis

Article Title: Interaction- and asymmetry-aware facial blendshape analysis for objective quantification of Parkinsonian hypomimia

Article References: Koyak, B., Menzel, T., Rodemann, M., Hennes, G., Spottke, A., Saxler, E., Bedarf, J., Faber, J., Sommerauer, M., Weydt, P., Reuter, M., Botsch, M., Wuellner, U., & Aziz, N. A. (2026). Interaction- and asymmetry-aware facial blendshape analysis for objective quantification of Parkinsonian hypomimia. npj Parkinson's Disease, 12(1), Article 231. https://doi.org/10.1038/s41531-026-01579-2

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01579-2

Keywords: Parkinson's disease, hypomimia, facial blendshapes, ARKit, digital biomarker, machine learning, facial asymmetry, ExpressionTracker, cross-validation, MDS-UPDRS, computer vision, neurodegeneration

The Golgi apparatus is best known as the processing and dispatch center of the secretory pathway. Proteins manufactured in the endoplasmic reticulum pass through its stacked membrane cisternae, where they are chemically modified, most notably through glycosylation, the attachment of sugar chains, and then sorted to their correct destinations, whether the plasma membrane, secretory vesicles, or lysosomes. The organelle also manufactures key lipids such as sphingomyelin and glycosphingolipids, participates in autophagosome formation, and runs its own quality-control degradation pathways. In other words, the Golgi sits at the crossroads of protein and lipid homeostasis, which is precisely why its failure could ripple through nearly every cellular process implicated in neurodegeneration.

That failure is not hypothetical. Postmortem studies of Alzheimer’s brains have long revealed fragmented, atrophied Golgi structures in affected neurons. More strikingly, when researchers expressed the amyloid precursor protein Swedish mutant in cells, the Golgi fragmented, and restoring Golgi architecture by expressing the structural proteins GRASP65 and GRASP55 dramatically reduced amyloid-beta production. In induced pluripotent stem cell-derived neurons from patients with sporadic Alzheimer’s disease, the fragmented Golgi phenotype persisted and, crucially, appeared before amyloid and tau pathology developed, suggesting that Golgi breakdown may be one of the earliest cellular events in the disease rather than a late consequence of it.

The strongest new argument for the Golgi’s relevance comes from large-scale human data. When the authors surveyed genetic studies, a striking pattern emerged: multiple independent analyses keep nominating Golgi-related genes as Alzheimer’s risk factors. An RNA-sequencing analysis found that Golgi-related gene ontology terms were elevated both in patients and in people with high polygenic risk scores for the disease, particularly in the temporal cortex. An X-chromosome-wide association study identified SLC9A7, a sodium/proton exchanger concentrated in the trans-Golgi network that maintains the organelle’s acidity, as the only genome-wide significant risk locus. Because Golgi luminal pH governs protein modification, glycosylation, and trafficking, its disruption could derail amyloid precursor protein processing among many other consequences.

Other risk genes reinforce the same theme. SORL1 and SORCS1, both well-established genetic risk factors, encode sortilin-family receptors that shepherd the amyloid precursor protein back to the trans-Golgi network, keeping it away from the endosomes where amyloidogenic cleavage predominates. Adaptor protein 4 complex genes AP4M1 and AP4E1, flagged by enhancer mapping of genome-wide association loci, regulate the precursor protein’s delivery to endosomes. A protective variant in NSF, a gene essential for Golgi reassembly and vesicle fusion, was identified in whole-exome sequencing of patients lacking the ApoE4 allele, hinting that Golgi integrity itself may confer resilience. Machine learning analysis of European GWAS data proposed COG7, a subunit of the complex that maintains Golgi structure and glycosylation, as a new risk gene, and multiancestry proteomic analyses independently nominated COG7, the trans-Golgi metalloprotease CPD, and the retrograde trafficking proteins SNX1, SNX32, and STX6 as candidate causal proteins.

Proteomics adds a second layer of evidence. A landmark 2022 study of more than 500 human brain samples found that Golgi and protein transport module signatures were reduced in asymptomatic Alzheimer’s brains and diminished further in symptomatic cases, correlating with cognitive scores. Perhaps most intriguingly, the extracellular matrix protein repertoire, the matrisome, showed the most prominent proteomic changes in the disease that were invisible at the RNA level, implying that post-translational modifications are the real driver. Since matrix proteins such as proteoglycans and collagen are extensively processed and glycosylated within the Golgi before secretion, Golgi dysfunction offers a mechanistically coherent explanation for this transcriptome-proteome discordance, and matrisome proteins are known to colocalize with amyloid plaques.

A 2024 glycomics study sharpened the picture further by mapping the N-glycan landscape of Alzheimer’s brains. The most altered sugar structures, sialylated and highly branched forms, are built inside the Golgi, and the affected glycoproteins clustered at synapses and the cell surface. Glycoform signatures tied to disease status involved L1CAM and NPTX1, markers of synaptic plasticity and synaptic loss, as well as ATP1B1, a subunit of the sodium-potassium pump essential for neural signaling. Expression of several Golgi-resident glycosylation enzymes, including MAN2A1, MGAT1, and members of the B3GALT, B4GALT, ST6GAL, and ST8SIA families, was altered across multiple brain regions, consistent with a systematic breakdown of Golgi-dependent protein modification that could directly undermine synapses.

Lipid biology supplies a third pillar. The Golgi is the primary site of ceramide processing through glucosylceramide synthase, whose levels fall in Alzheimer’s brains in correlation with ceramide accumulation, a lipid that promotes amyloid-beta production, oxidative stress, and neuronal death. The Golgi-localized enzyme neutral sphingomyelinase 2 drives the secretion of extracellular vesicles that can spread pathological tau between cells; inhibiting it reduced tau propagation and neurodegeneration in mouse models, and neuronal deletion of the gene reduced amyloid-beta production. Meanwhile, the oxysterol-binding protein OSBP1, which exchanges cholesterol and PI4P between the trans-Golgi network and the endoplasmic reticulum at membrane contact sites, regulates cholesterol distribution, mitochondrial fission, and retrograde trafficking, and its knockdown increased amyloidogenic processing of the amyloid precursor protein, linking Golgi-managed cholesterol homeostasis directly to plaque biology.

The authors synthesize these threads into four candidate pathogenic mechanisms. First, Golgi fragmentation may disrupt the normal segregation of the amyloid precursor protein and its processing enzymes, increasing their contact and boosting amyloid-beta generation, possibly even within the Golgi itself. Second, impaired trafficking between the Golgi and the endolysosomal system would trap the precursor protein in endosomes while starving lysosomes of properly sorted enzymes, simultaneously raising amyloid production and lowering its clearance. Third, defective glycosylation would alter countless proteins, including the amyloid precursor protein itself, whose O-glycosylation influences its trafficking and cleavage. Fourth, lipid dyshomeostasis would feed back on Golgi membrane integrity, creating a self-reinforcing vicious cycle that also damages mitochondria and the endoplasmic reticulum. Upstream triggers, including aging, DNA damage, oxidative stress, and neuronal hyperexcitability, as well as amyloid-beta and tau themselves, can all induce Golgi fragmentation, closing the loop.

Therapeutically, the possibilities are still largely conceptual but tantalizing. Restoring Golgi structural integrity, for example through nonphosphorylatable GRASP55/65 variants, could in principle ameliorate multiple disease processes at once. More targeted options include nSMase2 inhibitors, which have already shown benefits in Alzheimer’s mouse models; overexpression of SORL1, which redirects the amyloid precursor protein to the Golgi and lowers amyloid-beta output; and reinforcement of glycosylation or lipid balance through COG7, glucosylceramide synthase, or OSBP1. The authors are candid about the caveats: causality between Golgi dysfunction and Alzheimer’s pathogenesis has not been rigorously established, most evidence comes from familial disease models rather than the sporadic form that accounts for roughly 90 percent of cases, and because the Golgi handles so much cellular traffic, interventions could carry pleiotropic side effects. Still, with anti-amyloid antibodies delivering only modest clinical benefit, the review makes a compelling case that keeping this cellular post office running smoothly may be one of the most underexplored strategies for halting the disease, and that the humble Golgi apparatus deserves a central seat at the Alzheimer’s research table.

Subject of Research: The role of Golgi apparatus dysfunction in Alzheimer's disease pathogenesis and therapy

Article Title: Golgi dysfunction in Alzheimer disease: from human multiomic signatures to therapeutic targets

Article References: Song, J., Lee, S.-J., & Mook-Jung, I. (2026). Golgi dysfunction in Alzheimer disease: from human multiomic signatures to therapeutic targets. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01851-8

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01851-8

Keywords: Alzheimer's disease, Golgi apparatus, amyloid-beta, tau, glycosylation, lipid metabolism, SORL1, trans-Golgi network, multiomics, neurodegeneration, endolysosomal trafficking, therapeutic targets

The study, led by Monica Feole and Gorazd B. Stokin and published in Acta Neuropathologica, used human neurons derived from the H9 embryonic stem cell line, cultured for forty days until they developed mature axons. The researchers tagged TDP-43 with green fluorescent protein and filmed it under a high-resolution confocal microscope at four frames per second, capturing sixty-second movies of the protein’s movements inside living axons. To interpret what they saw, they compared TDP-43 against three well-characterized axonal cargoes with known transport behaviors: Rab5, an endosomal protein that mostly travels backward toward the cell body; synaptophysin, a synaptic vesicle protein that races forward to nerve terminals; and amyloid precursor protein, or APP, which moves in both directions with a slight forward bias.

The first surprise came from the directionality data. Using semi-automated particle tracking software, the team found that TDP-43 exhibited balanced bidirectional transport, with roughly equal proportions of particles heading toward the synaptic terminal and back toward the soma. This contrasts sharply with the reference cargoes, which showed their canonical patterns: Rab5 was predominantly retrograde, consistent with its role in endosomal recycling, while synaptophysin displayed a strong anterograde bias reflecting its kinesin-driven delivery to synapses. The balanced profile of TDP-43 suggests that its granules deliver messenger RNA to multiple axonal regions rather than a single destination, consistent with the protein’s role in maintaining RNA homeostasis throughout the neuron’s longest compartment.

Direction alone, however, tells only part of the story. The researchers employed a segmental analysis approach that divides each trajectory into vectorial segments, allowing frame-by-frame examination of velocity, pausing behavior, and directional reversals. This revealed that TDP-43 is a fast cargo. It spent significantly more time in anterograde motion than Rab5, paused less often, and reversed direction more frequently, all characteristics that align it with the fast-moving vesicular proteins synaptophysin and APP rather than the slower, pause-prone Rab5. Its total track lengths were comparable to synaptophysin and Rab5 but shorter than APP, which traveled the widest range of distances, hinting that TDP-43 granules may be heterogeneous in composition or in the motors they recruit.

Velocity distributions provided an even sharper clue about the underlying machinery. When the team plotted the speeds of anterograde segments, TDP-43’s velocities almost completely overlapped with those of APP, suggesting that both cargoes may share kinesin-dependent, plus-end-directed transport mechanisms. In the retrograde direction, by contrast, TDP-43’s velocities differed significantly from all three reference cargoes, implying that although the dynein-dynactin complex broadly mediates backward transport, its processivity is tuned in a cargo-specific manner, perhaps through unique adaptor proteins or post-translational modifications on membraneless ribonucleoprotein granules. Correlation analysis further showed that for TDP-43, longer runs correlated with higher speeds in both directions, a hallmark of processive motor engagement, with no significant difference in coupling strength between anterograde and retrograde movement.

To identify the actual molecular motors, the team turned to biochemistry. Co-immunoprecipitation experiments in the mature human neurons revealed that TDP-43 physically associates with kinesin light chain 1, or KLC1, the adaptor that links cargoes to the kinesin-1 family of anterograde motors, and with dynactin 1, a core component of the retrograde dynein complex. Notably, TDP-43’s binding to KLC1 was more robust than its binding to dynactin 1, a preference consistent with the strong anterograde characteristics observed in the live imaging. Reciprocal pulldowns confirmed the interactions: pulling down KLC1 brought along TDP-43 and the expected kinesin-5B partner, while pulling down dynactin 1 co-purified TDP-43 together with dynein intermediate chain 1.

The most striking result came from proximity ligation assays, a technique that detects proteins lying within forty nanometers of each other in their native environment. When the researchers knocked down KLC1 using short hairpin RNA delivered by lentiviral vectors, the TDP-43–KLC1 proximity signal in axons dropped dramatically, validating the specificity of the interaction. Then, using isoform-specific antibodies, they discovered that TDP-43 associates with all three mammalian kinesin-1 heavy chain isoforms: KIF5A, KIF5B, and KIF5C. This is significant because KIF5B is ubiquitously expressed while KIF5A and KIF5C are neuron-specific, and KIF5A is a recognized genetic cause of ALS. The engagement with all three isoforms suggests a flexible, redundant transport system in which distinct motor combinations could deliver different mRNA payloads to different axonal subdomains.

There was one more motor in the fleet. Because TDP-43’s anterograde dynamics resembled those of synaptophysin, which is transported by the kinesin-3 family member KIF1A, the team tested whether TDP-43 also engages this rapid synaptic vesicle motor. Co-immunoprecipitation in both directions confirmed the interaction, and proximity ligation assays placed TDP-43 and KIF1A within nanometers of each other along neuronal projections. The picture that emerges is of a multi-motor system: KIF1A may shuttle selected TDP-43 granules rapidly over long distances to distal synaptic terminals, while the kinesin-1 isoforms support more regulated delivery to intermediate axonal regions. Alternatively, distinct populations of TDP-43 granules, defined by their mRNA cargo or phase-separation properties, may preferentially recruit different motors.

Why does this matter for disease? In ALS, where TDP-43 accumulates abnormally in the cytoplasm, this flexible transport system may become compromised in multiple ways simultaneously. Pathological aggregates could sequester motor proteins or adaptor molecules, disrupting the delivery of mRNAs needed for local translation at synapses, including transcripts for cytoskeletal proteins, synaptic components, and nuclear-encoded mitochondrial proteins. Mutations in TARDBP and C9orf72 repeat expansions have already been linked to impaired mRNA trafficking, and mutations affecting the dynein-dynactin complex are associated with motor neuron disorders. The multi-motor redundancy documented in this study might normally provide resilience, allowing partial compensation when one pathway fails, but combined insults to cytoskeletal integrity, mitochondrial function, and RNA granule homeostasis could eventually overwhelm the system, driving the distal axonal degeneration that characterizes the dying-back model of ALS.

The findings also raise fundamental questions about how transport works without membranes. Classical models of axonal transport were built largely from studies of membrane-bound vesicles, where transmembrane proteins serve as docking sites for motor-adaptor complexes. TDP-43 travels in membraneless organelles, condensates of RNA and protein with no lipid bilayer, yet it clearly engages the same motor machinery. How motors recognize and bind these condensates, whether specific RNA sequences or RNA-binding protein motifs serve as adaptor recruitment sites, and whether the biophysical state of the condensates regulates motor engagement are all open questions. Previous work showed that some RNA granules hitchhike on lysosomes or mitochondria; this study demonstrates that TDP-43 can also associate directly with motors, suggesting both mechanisms may operate in parallel. By establishing a physiological baseline in human neurons, the work provides the framework against which ALS-linked mutations and patient-derived models can now be measured, and it points to axonal TDP-43 transport pathways as promising therapeutic targets for a disease that urgently needs them.

Subject of Research: Axonal transport mechanisms of the RNA-binding protein TDP-43 in human neurons and their relevance to ALS

Article Title: Multiple motor proteins regulate TDP-43 anterograde axonal transport

Article References: Feole, M., Devoto, V. M. P., Dragišić, N., Čarna, M., Klosterman, K., Limbaek-Stokin, C., Forte, G., Moya, K. L., Smith, R. A., Svendsen, C. N., & Stokin, G. B. (2026). Multiple motor proteins regulate TDP-43 anterograde axonal transport. Acta Neuropathologica, 152(1), Article 47. https://doi.org/10.1007/s00401-026-03071-w

Image Credits: AI Generated

DOI: 10.1007/s00401-026-03071-w

Keywords: TDP-43, axonal transport, amyotrophic lateral sclerosis, kinesin, KIF5A, KIF1A, KLC1, dynein, RNA-binding proteins, motor proteins, human neurons, neurodegeneration

The researchers began with chemistry. Using ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry, a technique capable of separating and identifying molecules with exquisite precision, they characterized the chemical composition of BSYZ. The analysis identified 105 distinct compounds in the formula, and supplementary data showed which of these were absorbed into the blood and which crossed into the brain, a crucial distinction for any candidate therapy targeting the central nervous system. The 105 compounds were distributed across the six herbs that make up the formula, giving the team a complete molecular inventory of what the remedy actually delivers to the body rather than relying on assumptions drawn from historical texts.

With the molecular inventory in hand, the team turned to biology. They mined publicly available transcriptomic datasets from the Gene Expression Omnibus, performing differential expression analysis and weighted gene co-expression network analysis, a statistical method that identifies groups of genes whose activity rises and falls together across disease states. This bioinformatic sweep uncovered 81 potential Alzheimer’s-related targets that the formula’s compounds might plausibly engage. But 81 targets is too many for a meaningful mechanistic story, so the researchers deployed an unusually rigorous filtering strategy: they screened the candidate list using 127 different machine learning models, then interpreted the consensus results with SHAP analysis, a technique borrowed from explainable artificial intelligence that quantifies how much each feature contributes to a model’s predictions.

The machine learning gauntlet distilled the field down to seven core genes: HIPK2, CXCR4, CCKBR, PTPN13, SFN, ALB and ALDH1A1. Each of these plays a documented role in Alzheimer’s-related pathological processes, from neuroinflammation and oxidative stress to synaptic dysfunction. The team then validated the computational predictions experimentally using RT-qPCR, a laboratory technique that measures messenger RNA levels and confirms whether the predicted genes are genuinely differentially expressed in disease. They were. Moreover, a stage-stratified transcriptomic analysis revealed that the expression of these seven genes changes dynamically as Alzheimer’s disease progresses, suggesting the formula’s targets are not static markers but active participants in the disease trajectory.

The biological effects of the formula were tested in a well-established animal model. Mice were treated with scopolamine, a drug that blocks acetylcholine signaling and reliably induces Alzheimer’s-like cognitive impairment, providing a fast and reproducible way to study memory deficits. When scopolamine-treated mice received BSYZ, the results were striking across multiple measures. In the Morris water maze, a standard test in which rodents must learn the location of a hidden platform, the treated animals showed ameliorated cognitive deficits compared with untreated scopolamine controls. Open field testing and histopathological examination using haematoxylin-eosin staining added further behavioral and structural evidence of neuroprotection.

Biochemical assays filled in the molecular picture behind those behavioral improvements. The researchers measured markers of oxidative stress, including superoxide dismutase and glutathione peroxidase, two antioxidant enzymes that protect neurons from damaging reactive molecules, and malondialdehyde, a byproduct of lipid peroxidation that serves as a fingerprint of oxidative damage. BSYZ treatment improved the antioxidant profile, indicating reduced oxidative stress. The formula also corrected cholinergic dysfunction, the loss of acetylcholine signaling that scopolamine induces and that mirrors a hallmark of Alzheimer’s pathology, by modulating acetylcholine, acetylcholinesterase and choline acetyltransferase. Finally, the treatment dampened neuroinflammation, the chronic immune activation in the brain that is increasingly recognized as a central driver of neurodegeneration.

To connect the seven core genes back to specific chemical compounds, the team employed molecular docking, a computational method that predicts how small molecules fit into the binding pockets of proteins, followed by 100-nanosecond molecular dynamics simulations that test whether those predicted complexes remain stable over time. The simulations tracked metrics such as root mean square deviation, root mean square fluctuations, radius of gyration and solvent-accessible surface area, all standard indicators of whether a protein-ligand complex is structurally stable or falling apart. The computational evidence pointed to two compounds in particular: isoquercitrin, a flavonoid glycoside, and epicatechin gallate, a polyphenol better known as a major active constituent of green tea. Both appeared to bind stably to CXCR4, a chemokine receptor, and CCKBR, the cholecystokinin B receptor, providing a plausible chemical-to-target link for two of the seven core genes.

The significance of this work extends well beyond a single herbal formula. Traditional Chinese medicine has long been criticized in Western pharmacology for its complexity, since multi-herb formulas contain hundreds of compounds acting on dozens of targets simultaneously, defying the one-drug-one-target paradigm that dominates pharmaceutical development. This study shows how that complexity can be tamed rather than dismissed. By combining untargeted chemical profiling with network analysis, machine learning consensus screening, explainable AI interpretation, transcriptomic validation and molecular simulation, the researchers built a framework in which every step is auditable and every conclusion is anchored to experimental data. The result is a mechanistic hypothesis precise enough to guide preclinical development.

The authors are careful about scope, and so should readers be. The animal model used here, scopolamine-induced cognitive impairment, captures certain features of Alzheimer’s disease but does not reproduce the full pathology of amyloid plaques and tau tangles that define the human condition. The molecular docking and dynamics results are computational evidence, not proof of binding in living tissue, and the RT-qPCR validation confirms gene expression changes rather than direct compound-target engagement in the brain. The paper itself was shared early as an accepted manuscript subject to further edits, carrying a permanent DOI and citable status. These caveats are standard for the field, but they mean the findings should be read as a rigorous foundation for further investigation rather than a clinical endorsement.

Nevertheless, the trajectory the study maps out is clear and potentially impactful. The demonstration that BSYZ acts through a multi-component, multi-target mechanism, engaging seven core genes that shift dynamically across disease stages, aligns with the growing recognition that complex neurodegenerative diseases may require correspondingly complex therapeutic interventions. The identification of isoquercitrin and epicatechin gallate as candidate bioactive molecules gives medicinal chemists concrete starting points for isolation, synthesis and optimization. And the systems pharmacology framework itself, integrating mass spectrometry, machine learning and experimental validation, is a reusable template that other research groups can apply to any traditional formula. For a disease that has defeated hundreds of single-target drug candidates, the message from this study is that ancient polypharmacy, viewed through the lens of modern computational biology, may hold lessons that reductionist approaches have missed.

Subject of Research: Systems pharmacology investigation of the traditional Chinese medicine formula Bushen-Yizhi as a multi-target therapy for Alzheimer's disease

Article Title: A system pharmacology framework to explore the therapeutic mechanism of Bushen-Yizhi formula against Alzheimer’s disease via integrating UPLC-Q-TOF-MS/MS, network analysis, machine learning and experimental validation

Article References: Zhang, J., Rao, H., Zhang, X., Zhao, S., Dai, Z., Tang, X., Cai, C., An, Y., Fang, S., Zhuo, Y., Li, H., & Fang, J. (2026). A system pharmacology framework to explore the therapeutic mechanism of Bushen-Yizhi formula against Alzheimer’s disease via integrating UPLC-Q-TOF-MS/MS, network analysis, machine learning and experimental validation. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05632-8

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05632-8

Keywords: Alzheimer's disease, Bushen-Yizhi formula, systems pharmacology, machine learning, UPLC-Q-TOF-MS/MS, molecular docking, molecular dynamics simulation, traditional Chinese medicine, neuroinflammation, oxidative stress, network analysis, scopolamine mouse model

The logistics of a motor neuron are staggering. These cells extend axons that can stretch up to a meter in the human body, and their distant terminals need a constant supply of fresh mitochondria, the organelles that generate the chemical energy ATP required for synaptic transmission and cellular survival. Moving mitochondria along the axon is an energy-intensive process in itself, and when that transport falters, the far reaches of the neuron are starved of power while damaged organelles pile up. Disrupted axonal transport has been implicated in ALS for years, and previous work had established that C9ORF72 motor neurons show cell-autonomous defects in mitochondrial motility and function. What remained unknown was whether the astrocytes surrounding those neurons—cells already known to contribute to non-cell-autonomous neurodegeneration through mechanisms such as reduced glutamate uptake and impaired lactate shuttling—also influence this transport machinery.

To find out, the team built a rigorous human stem-cell platform. They used induced pluripotent stem cell lines derived from three patients carrying the C9ORF72 repeat expansion, together with isogenic gene-corrected controls created through CRISPR–Cas9 editing, in which the mutation was removed. From these lines they generated highly enriched spinal cord-patterned astrocytes, more than ninety percent of which expressed the canonical astrocyte markers glial fibrillary acidic protein and S100B, as well as motor neuron cultures of which roughly half to sixty percent were ISL1/2-positive motor neurons. The mutant astrocytes carried hallmark C9ORF72 pathologies, including RNA foci and dipeptide repeat proteins, yet showed no differences in glutamate uptake or calcium wave propagation, meaning any effects on transport could not be attributed to those well-known astrocyte dysfunctions.

The central experiment was elegantly simple. The researchers selectively labeled motor neurons with a fluorescent mitochondrial marker, mito-DsRed2, and then imaged mitochondrial movement along a hundred-micrometer stretch of the proximal axon using live-cell time-lapse microscopy, generating kymographs from which they extracted two established metrics: the percentage of mitochondria that were motile and their average velocity. When genetically normal motor neurons were grown in physical contact with C9ORF72-mutant astrocytes, both measures dropped significantly compared with motor neurons cultured alone. Strikingly, when the same control neurons were paired with gene-corrected astrocytes, the deficit vanished entirely. Even more remarkable, mutant motor neurons cocultured with corrected astrocytes recovered both transport parameters to wild-type levels. In these mixed cultures, the phenotype of the neuron’s mitochondrial traffic was dictated not by the neuron’s own genome but by the genotype of its astrocyte neighbors.

Contact, it turned out, was essential. When the team treated control motor neurons with conditioned medium harvested from mutant astrocytes, mitochondrial motility was unaffected, indicating that secreted factors alone could not reproduce the damage; direct physical interaction between the two cell types was required. The specificity of the defect was equally revealing. Tracking HcT-labeled signaling endosomes, another vital axonal cargo, showed no transport changes in any coculture combination. The astrocyte effect was therefore cargo-specific, targeting mitochondria rather than causing a global collapse of axonal transport. The authors suggest this selectivity reflects distinct energetic dependencies: signaling endosomes fuel their movement with locally generated glycolytic ATP, whereas mitochondrial motility depends on membrane potential and calcium-regulated adaptors such as Miro, directly coupling transport to the bioenergetic state of the organelle itself.

That coupling became the thread the researchers followed next. Using Seahorse extracellular flux analysis, they measured oxygen consumption rates as a proxy for mitochondrial respiration. Because motor neuron cultures respire at nearly eightfold the rate of astrocytes alone, changes in coculture readings could be confidently attributed to the neurons. The results were unambiguous: coculture with astrocytes of either genotype boosted basal and maximal respiration relative to neuron monocultures, but pairing neurons with mutant astrocytes significantly reduced both parameters compared with pairing them with corrected astrocytes. A complementary assay using the potentiometric dye MitoTracker Red CMXRos confirmed that the steady-state mitochondrial membrane potential of motor neurons—mutant or normal—fell in the presence of mutant astrocytes and recovered with corrected astrocytes. The astrocyte genotype was directly modulating the bioenergetic health of neurons it touched.

The root of the problem lay within the astrocytes themselves. Isolated C9ORF72-mutant astrocytes showed significantly reduced basal, ATP-linked and maximal respiration compared with their gene-corrected counterparts, along with diminished glycolytic capacity, lactate production and glucose utilization. RNA sequencing, however, revealed no genotype-driven astrocyte reactivity, making a gain-of-toxic-function inflammatory mechanism unlikely. Intriguingly, when the team measured intracellular lactate in motor neurons using a genetically encoded FRET biosensor called Laconic, they found no significant differences across coculture conditions, suggesting that disrupted oxidative metabolism within astrocytes, rather than altered lactate transfer to neurons, mediates the transport deficit. The astrocytes were not failing to deliver fuel; they were failing in a way that somehow drains the neurons’ own power plants.

The therapeutic implication emerged from a rescue experiment targeting the master regulator of mitochondrial biogenesis. The team overexpressed three key metabolic genes in mutant astrocytes via lentiviral delivery: PPARGC1A (encoding PGC-1α), PPARGC1B (PGC-1β) and TFAM. PGC-1β proved toxic to the astrocytes, and TFAM, consistent with prior reports that it does not drive mitochondrial biogenesis, conferred no benefit. PGC-1α, by contrast, upregulated transcripts of the mitochondrial electron transport chain, including MT-CO2, MT-ND2, MT-CO3, MT-ND4 and MT-ATP6, and produced a trend toward increased respiration. When mutant astrocytes overexpressing PGC-1α were cocultured with motor neurons—mutant or corrected—mitochondrial motility and velocity were restored. Boosting the metabolic engine of the astrocyte alone was sufficient to repair the transport machinery inside genetically distinct neurons.

The findings reframe how scientists think about non-cell-autonomous degeneration in ALS. Rather than astrocytes poisoning neurons through inflammatory or excitotoxic signals, this work describes a bioenergetically coupled mechanism in which the metabolic competence of glia sets the ceiling for mitochondrial dynamics in neurons. The result also resonates with earlier animal work in SOD1 models of ALS, where PGC-1α activation preserved mitochondrial function and delayed disease progression, hinting that metabolic rescue of glia could be a broadly applicable strategy. The authors caution that much remains to be defined, including whether direct mitochondrial exchange, metabolite or lipid transfer, vesicular signaling or other modes of metabolic coupling connect astrocytic energy status to neuronal mitochondrial behavior, and whether similar mechanisms operate across other ALS genotypes and in sporadic disease, which accounts for roughly ninety percent of cases.

For a disease with no cure and only modestly effective therapies, the identification of an actionable, astrocyte-centered node is significant. If pharmacological activation of the PGC-1α pathway in glia can correct non-cell-autonomous mitochondrial dysfunction in C9ORF72-ALS, it opens a therapeutic window that does not require correcting the mutation inside every neuron. The study, funded in part by the Medical Research Council, the UK Dementia Research Institute and the My Name’5 Doddie Foundation among others, demonstrates with unusual clarity that in neurodegeneration, the health of a neuron may depend as much on the metabolic company it keeps as on its own genes—a lesson that could reshape drug discovery for ALS well beyond the C9ORF72 mutation that first revealed it.

Subject of Research: Non-cell-autonomous regulation of axonal mitochondrial transport by C9ORF72-mutant astrocytes in amyotrophic lateral sclerosis

Article Title: Astrocytes regulate axonal mitochondrial transport deficits in C9ORF72 amyotrophic lateral sclerosis motor neurons

Article References: Stavrou, M., Heffernan, Á. B., Carter, R. N., Dando, O., Jiwaji, Z., Burr, K., Nanda, J., Villarroel-Campos, D., Masoud Abdelhafid, A., Cholewa-Waclaw, J., Soong, D., Story, D., Schiavo, G., Hardingham, G. E., Chandran, S., & Selvaraj, B. T. (2026). Astrocytes regulate axonal mitochondrial transport deficits in C9ORF72 amyotrophic lateral sclerosis motor neurons. Nature Neuroscience. https://doi.org/10.1038/s41593-026-02464-0

Image Credits: AI Generated

DOI: 10.1038/s41593-026-02464-0

Keywords: amyotrophic lateral sclerosis, C9ORF72, astrocytes, motor neurons, mitochondrial transport, axonal transport, mitochondrial bioenergetics, PGC-1α, induced pluripotent stem cells, non-cell-autonomous neurodegeneration, CRISPR gene correction, live-cell imaging

The enzyme at the centre of the story is LRRK2, a large protein kinase encoded by one of the most important genes in Parkinson’s research. Pathogenic variants in LRRK2, such as the common G2019S substitution, drive disease by increasing the kinase activity of the protein. Kinases act as molecular switches, attaching phosphate groups to target proteins, and when LRRK2 runs too hot, its downstream targets are over-phosphorylated. The most informative of these targets are members of the Rab family, small GTPases that regulate traffic between cellular compartments. Rab10, in particular, carries a threonine at position 73 that is directly phosphorylated by LRRK2, making pRab10-Thr73 a widely used readout of LRRK2 pathway activity in accessible cells.

Why does this matter therapeutically? Because a wave of LRRK2 kinase inhibitors is advancing through clinical development, and these drugs are designed for patients whose disease is driven by excessive LRRK2 activity. If clinicians select patients purely on the basis of known pathogenic mutations, they may miss a much larger pool of individuals whose LRRK2 pathway is equally activated by other mechanisms. The Dundee-led study was designed to answer exactly that question: how common is elevated LRRK2 pathway activity among Parkinson’s patients who lack recognised pathogenic variants, and what might be driving it in those cases?

The researchers assembled a genetically enriched cohort of 181 Parkinson’s disease patients alongside 71 healthy controls. Rather than relying on targeted panels that test only a shortlist of known mutations, the team performed whole-exome sequencing, which reads the protein-coding regions of essentially every gene. This allowed them to identify both established pathogenic variants and rare variants of uncertain significance across the genome. In parallel, they quantified LRRK2-dependent phosphorylation of Rab10 at threonine 73 in blood neutrophils, the granulocytes that have become the standard peripheral cell type for this assay because they express LRRK2 at high levels and can be obtained from a simple blood draw.

The results provided a striking biological benchmark. Patients carrying the VPS35 p.D620N variant, a mutation in the retromer trafficking machinery that is known to activate LRRK2 signalling indirectly, showed marked elevation of phosphorylated Rab10 in their neutrophils. Because VPS35 p.D620N is an established cause of familial Parkinson’s disease that acts through LRRK2, the team used these carriers to define a reference threshold for what biologically meaningful pathway activation looks like. This is a subtle but important methodological advance: instead of relying on statistical outliers among controls, the threshold is anchored to patients whose disease mechanism is well understood.

Against that benchmark, the headline finding emerged. Fourteen percent of the Parkinson’s patients who had no recognised pathogenic variant showed LRRK2 pathway activation that was similar to, or even greater than, that of the VPS35 p.D620N carriers. In other words, roughly one in seven genetically unsolved patients in this cohort carried a molecular fingerprint indistinguishable from a known genetic cause of the disease. These individuals would be invisible to standard genetic counselling and would not be flagged by mutation-based screening, yet their biology points squarely at the LRRK2 pathway as a driver.

What could be pushing LRRK2 signalling into overdrive in patients without mutations in LRRK2 or VPS35? To begin answering this, the researchers took a functional genomics approach. They selected genes harbouring rare variants found in the subset of patients with increased LRRK2 pathway activity and tested each candidate experimentally. Using small interfering RNA to knock down the expression of these genes one at a time in A549 cells, a human lung carcinoma cell line that has become a workhorse for LRRK2 Rab phosphorylation assays, the team assessed whether reducing each gene’s activity changed LRRK2-dependent Rab10 phosphorylation. This exploratory screen identified several candidate genetic modifiers of LRRK2 signalling, among them NECAP2, a gene involved in clathrin-mediated endocytosis and adaptor protein trafficking.

The identification of NECAP2 and other candidates is best understood as hypothesis-generating rather than definitive. A knockdown screen in a cell line cannot prove that a rare variant in a patient caused their elevated pathway activity, and the authors are careful to frame the functional assessments as exploratory. Nevertheless, the logic of the approach is compelling: rather than guessing which rare variants matter based on evolutionary conservation or predicted protein damage alone, the team prioritised variants by asking whether perturbing the corresponding genes actually moves the needle on the disease-relevant molecular pathway. That functional filter is exactly what the field needs as whole-exome sequencing floods clinics with variants of uncertain significance.

The broader implication is a shift in how patients with Parkinson’s disease might be stratified for precision therapy. The authors argue for integrating functional pathway phenotyping, the direct measurement of LRRK2 activity in patient cells, with genomic analysis, so that trial enrolment and eventually treatment decisions rest on biology rather than on mutation status alone. As LRRK2-targeted therapies advance toward the clinic, this combined approach could identify the patients most likely to benefit, including those whose elevated kinase activity arises from undiscovered genetic modifiers rather than from the handful of variants currently listed as pathogenic. It also raises the possibility that some cases labelled idiopathic are, at the molecular level, genetic after all, simply through mechanisms that current diagnostic tests do not interrogate.

There are, of course, caveats to keep in view. The cohort was genetically enriched, meaning patients were selected partly because of family history or other genetic signals, so the fourteen percent figure may not generalise to the unselected sporadic population. Neutrophil pRab10 measurements reflect peripheral blood cells, not the dopaminergic neurons that degenerate in the disease, although the assay has been validated extensively as a surrogate of systemic LRRK2 activity. And the candidate modifiers, including NECAP2, require independent replication before they can inform diagnosis. Even so, the study delivers a clear and consequential message: measuring pathway activity, not just reading the genetic code, reveals a hidden layer of Parkinson’s disease biology, and that layer is large enough to matter for the next generation of LRRK2-targeted clinical trials.

Subject of Research: LRRK2 kinase pathway activity in genetically unsolved Parkinson's disease

Article Title: Functional pathway phenotyping reveals increased LRRK2 activity beyond recognised genetic causes of Parkinson’s disease

Article References: Pratuseviciute, N., Pirker, W., Huber, J., Gomes, S., Squires, I., Filipe Soares, R., Brücke, C., Zimprich, A., & Sammler, E. (2026). Functional pathway phenotyping reveals increased LRRK2 activity beyond recognised genetic causes of Parkinson’s disease. npj Parkinson's Disease. https://doi.org/10.1038/s41531-026-01575-6

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01575-6

Keywords: Parkinson's disease, LRRK2, Rab10 phosphorylation, VPS35 D620N, whole-exome sequencing, kinase activity, NECAP2, siRNA screen, precision medicine, genetic modifiers, neutrophils, patient stratification

The letter, authored by Maghfirotul Lathifah of PGRI Adi Buana Surabaya University in Indonesia and published on 8 October 2026, responds directly to a prospective five-year follow-up study by Partinen and colleagues that tracked changes in sleep characteristics among people with Parkinson’s disease. That study, appearing in the same journal, is among the recent efforts to move beyond cross-sectional snapshots, which capture sleep problems at a single moment, and instead document how sleep evolves over years in the same patients. The distinction matters because sleep in Parkinson’s is not static. It shifts with disease progression, with medication adjustments, and with the emergence of non-motor complications that can precede or accompany motor decline.

The technical case for this shift in perspective rests on how sleep pathology in Parkinson’s disease is organized. Sleep disturbance in these patients is not a single phenomenon but a cluster of distinct mechanisms. There is REM sleep behavior disorder, in which the normal muscle paralysis of dream sleep fails and patients physically act out their dreams, sometimes violently. There is severe fragmentation of nighttime sleep, driven by a combination of neurodegeneration in brainstem arousal and sleep-regulating circuits, nocturnal motor symptoms such as rigidity and off-period dystonia, and medication effects. There is excessive daytime sleepiness, which may reflect both nighttime disruption and direct involvement of wake-promoting systems including the orexin neurons of the hypothalamus. Each of these phenomena has a different underlying anatomy, a different time course, and, crucially, a different relationship to prognosis.

This is where the concept of functional trajectories becomes central. In Parkinson’s research, functional status refers to a patient’s capacity to perform daily activities independently, from dressing and eating to walking and managing medication. Clinical trials have historically emphasized motor scores, but what patients and families experience most acutely is the loss of functional independence. If specific sleep abnormalities reliably predict the slope of that decline, they become powerful prognostic tools, capable of identifying patients who need earlier intervention, closer monitoring, or more aggressive management of non-motor symptoms.

The evidence for such a link is already substantial in at least one domain. A 2019 study by Kim and colleagues, cited in the letter, found that REM sleep behavior disorder predicted functional dependency in early Parkinson’s disease. This finding fits within a broader literature showing that REM sleep behavior disorder is one of the strongest predictors of an aggressive disease phenotype, associated with faster progression of both motor and cognitive impairment. The mechanistic logic is compelling: the brainstem circuits that fail in REM sleep behavior disorder, particularly structures such as the sublaterodorsal nucleus and its connections, are embedded in the same networks that degenerate as the disease spreads, and their early failure may index a more widespread and rapidly advancing pathological process.

The five-year follow-up data from Partinen and colleagues add a longitudinal dimension to this picture. By measuring sleep characteristics repeatedly over five years, the study can distinguish between sleep problems that appear early and remain stable and those that emerge or worsen as the disease progresses. That temporal information is exactly what is needed to test whether sleep changes are merely consequences of advancing disease or whether they actively track and predict functional decline. A symptom that worsens in parallel with functional loss, and that can be measured objectively with tools such as polysomnography and validated questionnaires, offers clinicians a window into disease trajectory that standard motor examinations may miss.

The letter also widens the lens beyond the patient. A 2022 systematic review and meta-analysis by Sprajcer and colleagues, published in BMJ Open, documented significant sleep disturbance in caregivers of individuals with parkinsonism. This finding underscores a point that is often lost in clinical discussions: sleep pathology in Parkinson’s disease radiates outward. Nocturnal wandering in REM sleep behavior disorder can injure both patient and bed partner. Frequent nighttime awakenings mean that caregivers, who are frequently spouses of advanced age, lose sleep night after night, with documented consequences for their own health, cognitive function, and capacity to provide care. Sleep outcomes in this disease are therefore not purely individual clinical endpoints; they are markers of household-level burden.

What would it mean, in practice, to reorient clinical care around functional trajectories rather than symptom checklists? First, it would elevate sleep assessment from an optional add-on to a core component of neurological evaluation. Structured screening for REM sleep behavior disorder, objective measurement of sleep fragmentation where feasible, and systematic tracking of daytime sleepiness would become routine, not because sleep complaints deserve relief on their own, though they clearly do, but because their evolution carries prognostic information. Second, it would change how clinical trials are designed. If sleep measures predict functional dependency, they become candidate surrogate endpoints, allowing new therapies to be evaluated against outcomes that matter to patients over shorter observation periods. Third, it would sharpen the search for mechanism, since different sleep phenotypes may correspond to different patterns of neurodegeneration and thus to different therapeutic targets.

The letter’s argument also carries a caution about interpretation. Sleep symptoms and functional decline could be linked in several ways that are not mutually exclusive. Sleep disruption may be a cause of functional deterioration, through mechanisms such as impaired overnight clearance of pathological proteins, worsened daytime cognition and motor performance, and accelerated neuroinflammation. Alternatively, both sleep change and functional decline may be parallel outputs of the same underlying neurodegenerative process, making sleep a sensitive but not causal indicator. Disentangling these possibilities requires longitudinal designs with repeated measures of both sleep and function, precisely the kind of evidence the five-year follow-up study begins to provide. The letter’s contribution is to insist that this interpretive work be framed in terms of trajectories, not static symptom counts.

For a disease that affects millions worldwide and for which no therapy has yet been proven to slow its progression, the search for early, measurable, and meaningful prognostic markers is one of the most urgent tasks in neurology. The argument advanced in this letter is that sleep, long relegated to the status of a quality-of-life complaint, deserves a seat at the center of that search. If the way a patient sleeps over five years can reveal the path their disease will take, then every night of disturbed sleep is not just a symptom to be managed but a signal to be read, and reading it early may change how, and how effectively, the disease is fought.

Subject of Research: The relationship between sleep disturbances and functional trajectories in Parkinson's disease

Article Title: Beyond sleep symptoms: why functional trajectories matter in Parkinson’s disease

Article References: Lathifah, M. (2026). Beyond sleep symptoms: why functional trajectories matter in Parkinson’s disease. Journal of Clinical Sleep Medicine, 22(1), Article 190. https://doi.org/10.1007/s44470-026-00205-5

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00205-5

Keywords: Parkinson's disease, sleep disorders, REM sleep behavior disorder, functional dependency, sleep fragmentation, excessive daytime sleepiness, neurodegeneration, caregiver burden, prognosis, longitudinal study, movement disorders, Journal of Clinical Sleep Medicine

The research team, led by Theresa Lüth and colleagues at the Institute of Neurogenetics at the University of Lübeck, together with collaborators at the University of Luxembourg and the Medical University of Innsbruck, set out to solve a persistent technical problem. Short-read sequencing, the current gold standard for mitochondrial variant detection, relies on reads of only about 50 to 300 base pairs. That brevity creates uneven coverage, mapping biases, and vulnerability to contamination from NUMTs, fragments of mitochondrial DNA that have been pasted into the nuclear genome over evolutionary time. Short reads also cannot directly reconstruct a complete mitochondrial haplotype, the full sequence of a single mitochondrial genome, because each read captures only a tiny slice. Previous long-read approaches using Oxford Nanopore sequencing had achieved reliable detection only for variants above roughly 5 percent, and many full-length mitochondrial sequencing protocols relied on multiple overlapping PCR amplicons, which introduce their own amplification biases.

The Lübeck team’s solution was elegantly simple: amplify the entire roughly 16,600-base-pair mitochondrial genome in one single long-range PCR reaction, and then read each complete molecule end to end on the PacBio Vega platform. PacBio HiFi sequencing generates circular consensus reads with Phred quality scores of at least 30, corresponding to 99.9 percent per-base accuracy, which is precisely the fidelity needed to distinguish genuine low-frequency variants from sequencing noise. In their runs, more than 95 percent of all sequenced reads met this HiFi standard, and after filtering, the majority of reads spanned the full-length mitochondrial amplicon at approximately 16.6 kilobases. Average sequencing depth across the 24 samples reached a staggering 83,180-fold coverage, with uniform coverage across every position of the mitochondrial genome, evidence that the single-amplicon approach avoided the amplification bias that plagues overlapping PCR strategies.

Validation was the crux of the study, and the researchers designed a rigorous benchmarking experiment. They prepared predefined mixtures of two mitochondrial haplotypes, one from haplogroup D4e1’3 as the major component and one from haplogroup J1c2 as the minor component, at ratios of 5, 2, 1, and 0.1 percent. Because both samples had previously been characterized with Illumina NextSeq short-read sequencing, the expected variant profile of each mixture was known in advance, allowing the team to calculate sensitivity, precision, and the F1 score, the harmonic mean of the two. The results were striking. For mixtures between 5 and 1 percent, the F1 score was a perfect 1.0, meaning every expected variant was detected and no spurious variants appeared. Detected minor-variant levels closely matched the expected values, averaging 0.057 for the 5 percent mixture, 0.022 for 2 percent, 0.011 for 1 percent, and 0.001 for the 0.1 percent mixture.

Even at the extreme 0.1 percent level, where the researchers deliberately lowered the variant-calling threshold to 0.0005, all expected minor-haplotype variants were recovered, and sensitivity remained at 1.00. Ten additional variants discordant with the Illumina reference did pass the lowered threshold, dropping the F1 score to 0.91, but follow-up analysis suggested these were threshold-dependent noise rather than true signals. Two of them sat in the notoriously ambiguous homopolymeric D-loop region, and read-level assessment showed the discordant alleles were also present at low levels in the 5 percent mixture, simply below its higher calling threshold. Notably, all discordant variants occurred on molecules assigned to the major haplotype, not the minor component, and a graph-based tool called Himito found no evidence of NUMTs contamination anywhere in the dataset. The authors are careful to stress that these exploratory results should not be interpreted as establishing a general analytical detection limit of 0.1 percent.

The depth of sequencing also proved to be a resource that could be traded for throughput. By systematically downsampling the data from roughly 70,000-fold coverage down to 300-fold, the team showed that accuracy and sensitivity remained very high at depths above 1,500-fold for mixtures of 1 percent or more, and the F1 score stayed at 1.00 across all tested depths for the 5 percent mixture. The practical implication is considerable: with the 230 barcodes available on a single PacBio Vega SMRT Cell, each sample would still receive approximately 13,000-fold mitochondrial coverage, ample for accurate detection of heteroplasmy at the 1 percent level. In other words, large cohorts could be multiplexed without sacrificing the low-frequency sensitivity that makes this technique valuable.

Beyond counting individual variants, the long reads allowed something short reads fundamentally cannot: direct reconstruction of complete mitochondrial haplotypes at the single-molecule level. When the researchers classified individual full-length reads according to haplotype-specific marker variants, the observed proportions of minor-haplotype reads closely matched the expected mixture ratios, and visualization of representative reads from the 1 percent mixture showed that informative variants consistently co-occurred on the same sequencing molecule. This phasing capability matters because it confirms that variants arising from the same mitochondrial genome can be linked together, a prerequisite for understanding how mitochondrial populations evolve within cells and tissues.

With the workflow validated, the team applied it as a proof of principle to a biological question at the heart of Parkinson’s disease research. They studied fibroblast cell lines from five carriers of the LRRK2 p.Gly2019Ser variant, the most common genetic cause of familial Parkinson’s disease: three affected by the disease and two unaffected. The cells were cultured in parallel and sampled at passages 1, 4, 8, and 12 over 84 days, and mitochondrial DNA was extracted and sequenced at each time point. Restricting their analysis to variants above 1 percent heteroplasmy, based on the mixture validation, the researchers observed a decrease in the number of detected heteroplasmic variants across passages, confirmed by a linear mixed-effects model showing significantly fewer variants at passage 12 compared with passage 1. In exploratory analyses, the heteroplasmic variant load was higher in fibroblasts from affected carriers than unaffected carriers, and it was associated with older age at sample collection, though the authors caution that the small number of cell lines demands careful interpretation.

Perhaps most intriguing were the variant-specific trajectories the long-read data revealed. In one fibroblast line from an affected carrier, a synonymous variant in MT-CO2 fell from 20.5 to 7.7 percent heteroplasmy across passages, and a synonymous variant in MT-ND5 dropped from 23.3 to 8.3 percent, while a missense variant in MT-ND2 rose steadily from 8.4 to 57.5 percent. These opposing patterns, with some variants declining and others expanding, suggest that selective pressures or clonal expansion processes actively shape mitochondrial heteroplasmy during cell culture, consistent with recent single-cell work showing that selection, rather than random drift, governs heteroplasmy levels in dividing cells. No structural variants such as deletions were detected above the 1 percent threshold in the analyzed samples, and no consistent pattern distinguished affected from unaffected carriers, underscoring the substantial inter-individual variability in heteroplasmy dynamics.

The study is not without limitations, which the authors lay out candidly. Long-range PCR risks primer dropout when polymorphisms fall within primer-binding sites, variants in those regions cannot be reliably assessed, PCR amplification can introduce low-level polymerase errors that the benchmarking design does not fully capture, and the PCR-based enrichment erases native DNA methylation, precluding epigenetic analysis. The validation also focused on single-nucleotide variants rather than structural variants. Still, the achievement stands: this is the first demonstration that PacBio HiFi sequencing can detect mitochondrial heteroplasmy with high accuracy down to 1 percent using a haplotype mixture benchmarking framework, a substantial advance over the roughly 5 percent limit previously reported for Oxford Nanopore sequencing under comparable conditions. As the cost of long-read sequencing continues to fall, this workflow offers researchers a powerful new lens for studying mitochondrial variation in aging, cancer, mosaic somatic disease, and neurodegeneration, and future studies in larger cohorts will determine whether the elevated variant load seen in affected LRRK2 carriers holds up as a genuine molecular signature of Parkinson’s disease.

Subject of Research: High-accuracy detection of mitochondrial DNA heteroplasmy using PacBio HiFi long-read sequencing in Parkinson's disease

Article Title: Long-read sequencing enables high-accuracy mitochondrial heteroplasmy detection in Parkinson’s disease

Article References: Lüth, T., Schaake, S., Much, C., Belyea, M. M., Seibler, P., Grünewald, A., May, P., Klein, C., Weissensteiner, H., & Trinh, J. (2026). Long-read sequencing enables high-accuracy mitochondrial heteroplasmy detection in Parkinson’s disease. BMC Genomics, 27(1), Article 831. https://doi.org/10.1186/s12864-026-13426-y

Image Credits: AI Generated

DOI: 10.1186/s12864-026-13426-y

Keywords: mitochondrial DNA, heteroplasmy, PacBio HiFi, long-read sequencing, Parkinson's disease, LRRK2, variant calling, fibroblasts, haplotype phasing, BMC Genomics, NUMTs, benchmarking

Isolated REM sleep behavior disorder, or iRBD, is a sleep condition in which people physically act out their dreams, sometimes shouting, punching, or kicking during the night. The reason it attracts so much attention from neuroscientists is that a large proportion of people with iRBD eventually develop Parkinson’s disease or a related disorder, often years or even decades after the sleep problem first appears. That makes people with iRBD an ideal population in which to study the prodromal phase of Parkinson’s, the long silent stretch before the classic motor symptoms of tremor, stiffness, and slowness of movement become obvious enough for a clinical diagnosis. If researchers can detect subtle motor decline during this prodromal window, they could identify candidates for future preventive treatments and measure whether those treatments actually slow the disease.

The study enrolled twenty-six healthy controls, twenty-two patients with iRBD, and twenty-three patients with early-stage Parkinson’s disease. Every fourteen days, for twenty-four months, each participant completed a set of tasks on a smartphone covering four distinct motor domains: speech, psychomotor performance, hand tremor, and a U-turn task. The speech tasks included sustained phonation, reading aloud, and rapid repetition of syllables, a test known as oral diadochokinesis. The psychomotor component involved tapping exercises, while the tremor task asked participants to hold the phone in a way that allowed its motion sensors to record any shaking of the hand. The U-turn task captured information about turning speed, an aspect of movement that is known to be affected early in parkinsonism. All of this was done remotely, without clinic visits, which is precisely what makes the approach attractive for large-scale trials.

The results, reported by Vojtěch Illner and colleagues including corresponding author Jan Rusz, reveal a striking asymmetry between the two patient groups. In the iRBD group, disease progression showed up in two places: a measure called monopitch derived from reading aloud, which reflects a flattening of pitch variation in the voice, and a slowing of turn speed in the U-turn task. Both of these changes reached statistical significance at the p < 0.05 level over the two-year follow-up. In the early Parkinson’s disease group, the clearest longitudinal signal was a shortening of the time to the first voice break during sustained phonation, again significant at p < 0.05. In other words, the voice and turning tasks carried genuine information about disease trajectory, while other measures behaved differently.

That difference matters because many of the smartphone measures proved excellent at telling groups apart at a single point in time but failed to track change over the two years. Several speech, psychomotor, and U-turn measures showed adequate cross-sectional sensitivity, meaning they could reliably distinguish people with iRBD or early Parkinson’s disease from healthy controls when everyone was compared at the same moment. Cross-sectional discrimination and longitudinal sensitivity are not the same thing, however. A measure can separate a patient from a control on any given day yet remain stable within an individual, making it useless for monitoring progression. The study’s two-year design allowed the team to separate these two properties, something shorter studies often cannot do.

Perhaps the most instructive finding of the study concerns the learning effect. When people repeat the same task every two weeks, they improve at it, and that improvement can mask or mimic true disease change. The researchers found a significant learning effect during the first year of monitoring in measures derived from oral diadochokinesis, the rapid syllable repetition task, as well as from tapping and hand tremor. In practical terms, participants got faster or steadier simply through repetition, and only after roughly a year did this practice effect plateau. For anyone designing a future remote monitoring trial, this is a crucial piece of guidance: measures derived from these tasks need either a stabilization period, careful modeling of the learning curve, or exclusion from progression analyses, otherwise the data will reflect practice rather than biology.

The technical achievement behind these results should not be understated. Modern smartphones contain high-precision accelerometers, gyroscopes, and microphones that can capture movement and voice at sampling rates more than sufficient for detecting the small changes that characterize early neurodegeneration. Speech analysis can quantify pitch variability, timing, and stability of phonation with millisecond and hertz-level resolution. Motion sensors can decompose a turning maneuver into speed and smoothness. By administering these tasks every fourteen days, the study generated a dense longitudinal record for each participant, far richer than what annual clinic visits could provide. This density is what allowed the researchers to observe gradual drifts in voice and turning measures that would otherwise be lost in the noise of day-to-day variation.

For the field of digital biomarkers in Parkinson’s disease, the study functions as a roadmap rather than a final answer. The authors describe their work as guidance for future remote smartphone trials that integrate diverse motor domains to monitor prodromal and early parkinsonism. The message is twofold. First, speech measures, particularly those capturing pitch characteristics during reading and voice stability during phonation, together with turning speed, appear to carry genuine longitudinal signal in the populations most at risk. Second, the tasks that seem most intuitive, such as tapping speed and tremor measurement, are the ones most vulnerable to practice effects in the first year, and therefore require the most careful handling. Trials aimed at disease modification, where the endpoint is slowing of progression, will depend on measures that are both sensitive to change and robust to repetition.

The broader implications reach beyond Parkinson’s research. Remote smartphone monitoring could eventually allow neurologists to follow patients continuously at home, reducing the burden of travel and capturing the real-world variability of symptoms that clinic assessments miss. For people with iRBD, many of whom are keenly aware of their elevated risk, a regular two-minute phone battery could offer an objective, quantified view of their own trajectory, replacing anxiety with data. And for pharmaceutical companies developing therapies intended to be given before symptoms appear, validated digital endpoints collected at home could dramatically shrink and shorten the trials needed to prove that a drug works. The present study, with its modest sample sizes and two-year horizon, is an early step on that path, but a carefully designed one.

There remain caveats worth keeping in mind. The cohorts were relatively small, with twenty to twenty-six participants per group, and the findings will need replication in larger and more diverse populations. The study also monitored participants for two years, a period in which only a subset of people with iRBD can be expected to convert to overt Parkinson’s disease, so the full predictive power of the smartphone measures for identifying who will convert remains to be established. Still, the core conclusion stands on solid ground: a consumer device carried in a pocket, paired with well-chosen tasks and a smart analysis plan, can detect meaningful motor change in the earliest stages of Parkinson’s disease, provided researchers respect the learning effects that come with repetition. As remote monitoring matures, the smartphone may well become the stethoscope of neurology, and studies like this one are teaching clinicians exactly where to listen.

Subject of Research: Smartphone-based remote motor monitoring for detecting disease progression in isolated REM sleep behavior disorder and early Parkinson's disease

Article Title: Two-year smartphone motor monitoring in isolated REM sleep behavior disorder and Parkinson’s disease

Article References: Illner, V., Novotný, M., Kouba, T., Tykalová, T., Šimek, M., Šubert, M., Sovka, P., Švihlík, J., Růžička, E., Šonka, K., Dušek, P., & Rusz, J. (2026). Two-year smartphone motor monitoring in isolated REM sleep behavior disorder and Parkinson’s disease. npj Parkinson's Disease. https://doi.org/10.1038/s41531-026-01588-1

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01588-1

Keywords: Parkinson's disease, isolated REM sleep behavior disorder, digital biomarkers, smartphone monitoring, speech analysis, motor progression, prodromal Parkinson's, remote assessment, hand tremor, U-turn task, learning effect, npj Parkinson's Disease